Heffter Research Institute provides Roland
with a large portion of his clinical research funding
In a Nutshell:
Leading psychopharmacologist Roland Griffiths will disclose the ways that psychedelic drugs can be used to create spiritually meaningful, personally transformative experiences for all patients, especially the terminally ill.
Forty years after the Nixon administration effectively shut down research on psychedelic drugs, Roland Griffiths helped reopen it. One of the nation’s leading psychopharmacologists, Griffiths’ research focuses on the behavioral and subjective effects of mood-altering drugs. He is the lead investigator of the Psilocybin Research Initiative at Johns Hopkins, which includes studies of psilocybin occasioned mystical experience in healthy volunteers and cancer patients, and a pilot study of psilocybin-facilitated smoking cessation. Roland is a Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine. He has been a consultant to the National Institutes of Health, and to numerous pharmaceutical companies in the development of new psychotropic drugs.
Explore the secrets and wonders of the brain, from the amazing wisdom of the cerebral cortex, to the mind’s invisible wounds and dysfunctions; from the latest neuroscience, to the vast remaining mysteries of our most inscrutable organ. Our explorers of the mind’s unknowns include a spiritual psychedelic researcher; a positive psychology detective; actors whose craft makes them expert caretakers for dementia patients; and a psychiatrist who, ironically, uses our own addictive behavior to combat other, more dangerous addictions.
Dr. Griffiths discusses the past, present, and future of classic hallucinogen research in this excellent interview:
Read under science or spirituality on Our Amazing World to learn more about studies funded by Heffter Research Institute.
Griffiths' TEDTalk from 2009:
Courageous Heffter-Funded Work at
UAB School of Public Health that Changes Perceptions & Could Change Your World
Griffiths' historic original research from the journal Psychopharmacology:
Candid Panel Discussion:
The Next Decade -- Where Can We Go?
Consciousness & Quantum Behavioral Change
Roland Griffiths, Ph.D., David E. Nichols, Ph.D., Stephen
Ross, M.D., Henry Stapp, Ph.D., Franz X. Vollenweider, M.D.
"More real and more true than everyday waking consciousness"
- Roland Griffiths, Ph.D.
Psilocybin for the Treatment of
Anxiety Associated with Cancer
Helping cancer patients with existential anxiety is a task that our current healthcare system does not handle well. Treatment with traditional pharmacotherapy like antidepressants (i.e. Prozac) or benzodiazepines (i.e. Xanax) has limited efficacy and little research, and is considered 2nd line compared to psychotherapy and alternative therapies.
Dr. Charles Grob's 2011 pilot study using psilocybin to treat cancer anxiety was the first study in over 40 years using 'psychedelics' to treat this indication.
Learn more about the power of awe,
how it relates to the mystical experience
caused by psilocybin, and how that might
help patients cope with a life-threatening
or terminal illness diagnosis.
Is it unethical for the National Institutes of
Health (NIH) and NIMH not to fund research that
could potentially change treatments and attitudes toward mental illness in America, at best, or
to learn more about the brain, at minimum?
National Institute of Mental Health director Thomas Insel discusses shortcomings of mental health leading up the the 2015 Davos World Economic Forum, which focused on mental health:
Watch Director Insel and top meditation researcher Richard Davidson deconstruct mindfulness meditation.
Ayahuasca, also called "vine of the soul," is another classic hallucinogen that has been used for centuries in spiritual healing practices by indigenous peoples of South America.
Watch Dr. Gabor Maté, world-renowned addiction and palliative care specialist, discuss addiction and how ayahuasca, when used appropriately, offers patients insight about self-destructive behaviors.